1. Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment
- Author
-
Shuang Li, Xianhong Liu, Liang Zhang, Ying Cheng, Xiubao Ren, Shuang Zhang, Jingjing Liu, Ying Liu, Lianwei Bai, and Changliang Yang
- Subjects
Adult ,Male ,non‐small cell lung cancer ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Multivariate analysis ,medicine.medical_treatment ,Immune checkpoint inhibitors ,Adenocarcinoma of Lung ,Immune checkpoint inhibitor ,rapid progression ,Single Center ,lcsh:RC254-282 ,Asian People ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Lung cancer ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies ,business.industry ,Hazard ratio ,Original Articles ,General Medicine ,Immunotherapy ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Survival Rate ,Carcinoma, Squamous Cell ,Disease Progression ,Female ,Original Article ,Non small cell ,business ,Progressive disease ,Follow-Up Studies - Abstract
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non‐small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non‐negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of RP and to identify related factors. Methods We retrospectively evaluated Chinese patients who had received an ICI as second‐line or later treatment for locally advanced or metastatic NSCLC at a single center. We defined RP as radiological progression at the first response assessment (
- Published
- 2020